Skip to content

The Prognostic Impact of Selenium On Critical Surgical Patients

The Prognostic Impact of Selenium On Critical Surgical Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04662242
Enrollment
36
Registered
2020-12-10
Start date
2020-12-01
Completion date
2022-11-16
Last updated
2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Selenium Deficiency, Trace Element Deficiency, Acute Abdomen, Sepsis

Brief summary

Selenium is an important trace element for human for its multiple roles such as the antioxidant activity. Previous evidences showed that critically ill patients may benefit from selenium supplement but the dose and results are controversial. Patients after operations for acute abdomen usually suffer from sepsis and stress. The aim of this study is to investigate the efficacy of selenium replacement in critical patients of acute abdomen, to see the impact on prognosis.

Detailed description

Acute abdomen is a common surgical emergency and is often the result of peritonitis due to an acute inflammatory process within abdominal cavity. Many of the patients with acute abdomen have severe sepsis and are critically ill that require an emergency surgery. The mortality rate of such patients are high because these patients usually have a profound pathophysiological dysregulation and multiple organ dysfunction. One of the mechanism of is the loss of anti-oxidative capacity of cells that fail to recover from ischemic-reperfusion injury. Selenium is an important cofactor that participate in the antioxidant activity of glutathione peroxidase reaction. There are evidences that critically ill patients may benefit from selenium supplement by better outcome and less mortality but the dose and results are still heterogenous and inconclusive. The aim of this study is to investigate the efficacy of selenium replacement in critical patients of acute abdomen, to see if there is a significant impact on prognosis, and to establish a clinical guide in the future.

Interventions

Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days

DRUGnormal saline

normal saline 100ml iv infusion for 7 days

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Intensive care unit (ICU) patients receiving abdominal surgeries for acute abdomen * within 48 hours post-operatively * stay in ICU for more than 48 hours * meets sepsis criteria of Sepsis-3 (2016)

Exclusion criteria

* liver cirrhosis Child-Pugh score B or C * breastfeeding or pregnancy * allergy yo selenium * vegetative status or irreversible diseases with life-expectancy fewer than 28 days * End-stage renal disease under dialysis * Human immunodeficiency virus infection * neutropenia not due to sepsis (granulocyte \< 1000/mm3) * Heart failure (New York Heart Association class III-IV) or recent myocardial infarction (within 6 weeks) * post cardiopulmonary cerebral resuscitation within 4 weeks * taking immunosuppressants * receiving anti-cancer therapy * signed do not resuscitation * joined other clinical research

Design outcomes

Primary

MeasureTime frameDescription
mortality rate30 daymortality rate in 30 days

Secondary

MeasureTime frameDescription
hospital length1 yearhospital length for current admission
ventilator length1 yearventilator length for current admission
complication rate30 dayscomplication rate within 30 days
organ failure rate30 daysorgan failure rate within 30 days

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026